DARETABART
UNII G3JN6K8LV3

Substance Identification & Data

This profile provides standardized clinical and technical data for Daretabart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) G3JN6K8LV3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3011830-62-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

G3JN6K8LV3

CAS Registry Number

3011830-62-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DARETABART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C215731

National Cancer Institute reference terminology for clinical and research data.

INN ID

13434

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Daretabart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

DARETABART

Common Names & Synonyms

DARETABART [INN]

H-GAMMA1 HEAVY CHAIN (1-443) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV1-42*04 (86.5%) -(IGHD) -IGHJ4*01 (71.4%) Q120>T (105), G121>Q (106), T122>G (107) /HOMO SAPIENS IGHV1-46*01 (71.9%) -(IGHD) -IGHJ5*01 (75.0%) Q120>T (105), G121>Q (106), T122>G (107), L123>S (108), CDR-IMGT (8.8.6) (26-33.51-58.97-102)) (1-113) -HOMO SAPIENS IGHG1*03, G1M3, NG1M1 CH1 R120, CH3 E12, M14, 5-G1V20 CH2 A105 (CH1 R120 (210) (114-211), HINGE 1-15 (212-226), CH2 K105>A (318) (227-336), CH3 E12 (352), M14 (354) (337-441), CHS (442-443)) (114-443)), (216-220')-DISULFIDE WITH L-KAPPA LIGHT CHAIN (1'-220') (V-KAPPA MUSMUS/HOMSAP (MUS MUSCULUS IGKV1-110*01 (94.0%) -IGKJ5*01 (100%)/HOMO SAPIENS IGKV2D-29*02 (82.0%) -IGKJ2*01 (81.8%) Q120>A (106'), I126>L (112'), CDR-IMGT (11.3.10) (27'-37'.55'-57'.94'-103')) (1'-113') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')); DIMER (222-222'':225-225'')-BISDISULFIDE, PRODUCED IN YB2/0 CELL LINE, GLYCOFORM ALFA

IMMUNOGLOBULIN G1 (318-ALANINE), ANTI-(HUMAN GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL RPL001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RPL001 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS GD2 (DISIALOGANGLIOSIDE GD2)), MONOCLONAL ANTIBODY;

External Clinical & Regulatory Resources

Previous UNIIG3JDL94B7V

Next UNIIG3JV3W2XC7